-
G7 to launch 'alliance' countering China's critical mineral dominance
-
Wallaby boss Schmidt wary of Ford's 'triple threat'
-
Swedish hate-crime trial shines light on far-right 'fitness clubs'
-
Trump call for nuclear tests sows confusion
-
Chinese EV giant BYD says Q3 profit down 33%
-
ECB holds rates steady with eurozone more resilient
-
Independent Macau media outlet says it will close by December
-
Shares in Jeep-maker Stellantis slump despite rising sales
-
Shelton beats Rublev to reach Paris Masters last eight
-
Trump stirs tensions with surprise order to test nuclear weapons
-
S.Africa court rules ANC leader Luthuli was killed in apartheid 'assault'
-
Stocks slide as investors digest Trump-Xi talks, earnings
-
No GDP data released as US shutdown bites
-
PSG's injured Doue to miss Bayern match, out for several weeks
-
Litchfield ton guides Australia to 338 in World Cup semis
-
S.Africa court rules ANC leader Luthuli killed in apartheid 'assault'
-
With inflation under control, ECB holds rates steady again
-
Nigerian designer embraces 'clashes' and 'chaos' at Lagos Fashion Week
-
Nissan says expects $1.8 bn operational loss in 2025-26
-
Italy court stalls Sicily bridge, triggers PM fury
-
Marseille midfielder Nadir stable after on-pitch collapse
-
Saudis turned down Messi stint ahead of 2026 World Cup, says official
-
Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera
-
Universal says struck first licensing deal for AI music
-
France arrests five new suspects over Louvre heist: prosecutor
-
Record Vietnam floods kill 10, turn streets into canals
-
Trump orders US to start nuclear weapons testing
-
'Significant' Xi, Trump talks win cautious optimism in China
-
French justice minister visits jailed former president Sarkozy
-
Eurozone growth beats expectations in third quarter
-
Bali trial begins for 3 accused of Australian's murder
-
Dutch election a photo finish between far-right, centrists
-
IOC removes Saudi Arabia as host of inaugural Esports Olympics
-
Russia batters Ukraine energy sites, killing two
-
Shell's net profit jumps despite lower oil prices
-
Pakistani security source says Afghanistan talks 'likely' to resume
-
Fentanyl, beans and Ukraine: takeaways from Trump-Xi's 'great meeting'
-
Branson's Virgin moves closer to launching Eurostar rival
-
Russia hits Ukraine energy sites, killing one, wounding children
-
Asia markets fluctuate as investors mull Trump-Xi talks
-
Trump, Xi ease fight on tariffs, rare earths
-
Volkswagen posts 1-billion-euro loss on tariffs, Porsche woes
-
'Fight fire with fire': California mulls skewing electoral map
-
Fentanyl, beans and Ukraine: Trump hails 'success' in talks with Xi
-
'Nowhere to sleep': Melissa upends life for Jamaicans
-
Irish octogenarian enjoys new lease on life making harps
-
Tanzania blackout after election chaos, deaths feared
-
G7 meets on countering China's critical mineral dominance
-
Trump hails tariff, rare earth deal with Xi
-
Court rules against K-pop group NewJeans in label dispute
US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
K.Thomson--BTB